Dec 12, 2024 activistcompany

DOMA Perpetual Capital Management Announces Intent to Nominate Director Candidates to Pacira BioSciences, Inc. (PCRX)

Key Summary: On March 14, 2025, DOMA Perpetual Capital Management announced the nomination of three director candidates, expressing concerns over the company's 76% decline in stock performance over the past decade and misaligned management compensation.

Market Cap: $1 billion | Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

On December 11, 2024, DOMA Perpetual Capital Management (4.14%) announced its intent to nominate four independent director candidates at the 2025 annual meeting. DOMA expressed confidence in Pacira’s intellectual property and criticized the stock as significantly undervalued. It urged the company to initiate a tender offer for 10 million shares using cash on hand and execute its approved $150 million buyback program supported by strong free cash flow. Source

On March 14, 2025, DOMA Perpetual Capital Management announced the nomination of three director candidates citing concerns over company's poor stock performance (down 76% in the last decade) and misaligned management compensation. Source

More like this

Value Base Ltd Opposes Poison Pill, Citing Shareholder Harm at Perion Network Ltd (PERI)

Engine Capital Nominates Directors to Push for Change at Lyft (LYFT)

Woodbridge Nominates Two Directors to Replace Retiring Thomson Reuters (TRI) Board Member

BML Capital Calls for Liquidation and Cash Return at Elevation Oncology (ELEV)

Soleus Capital Urges ESSA Pharma (EPIX) to Liquidate and Return Cash to Shareholders

Ocho Publishes Presentation to the Board of Digimarc Corp (DMRC)